Tailoring preventive treatment for hemophilia a
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at how well a newer preventive treatment for hemophilia A works in everyday life. It collects real-world information from patients to help doctors tailor clotting therapy better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have hemophilia A, either severe or moderate.
- You should not have an active inhibitor, or if you have a history of one, it must be at a very low level.
- You need to be on a preventive treatment (like factor VIII or emicizumab) since at least March 1, 2025.
- You must be a patient at one of the eight participating hospital centers in the BERHLINGO network.
- You must agree (or not object) to take part in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
This study collects real-world information on how well a personalized clotting-factor plan helps people with hemophilia A get rid of inhibitors. It may help doctors refine treatment for patients who develop antibodies that block factor therapy.
This study tests a new preventive treatment (NXT007) to help stop bleeding episodes in infants and children with hemophilia A. It aims to see if this treatment reduces the number of bleeds and improves quality of life.
This study looks at how prophylactic treatment for hemophilia affects your daily life, sleep, and feelings about your health. It compares different types of clotting factor concentrates to see if one is easier to manage than the other.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study tests a new medicine called SR604, given as a shot under the skin, to help prevent bleeding in people with hemophilia A or B. If it works, it could reduce the number of bleeding episodes and make daily life easier.
Hear when a new Hemophilia A Patient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.